← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Janus-associated kinase (JAK) inhibitors
baricitinib
L04AF02
Forms & Strengths
- film-coated tablets: 1mg, 2mg, 4mg
- oral administration
Adult Dosing
- 2mg or 4mg once daily for rheumatoid arthritis
- 4mg once daily for atopic dermatitis
- 4mg once daily for COVID-19
Pediatric Dosing
- Not established for patients under 18 years
- Use in juvenile idiopathic arthritis is being studied
Indications
- Moderate to severe active rheumatoid arthritis
- Moderate to severe atopic dermatitis
- Hospitalized patients with COVID-19
Mechanism of Action
- Janus kinase (JAK) 1 and 2 inhibitor
- Blocks intracellular signaling of multiple cytokines
Contraindications
- Active serious infection
- Active tuberculosis
- Severe hypersensitivity to baricitinib
Adverse Reactions
- Upper respiratory tract infections
- Nausea
- Headache
- Blood creatine phosphokinase elevations
Drug Interactions
- Concomitant use with biologic DMARDs or potent immunosuppressants not recommended
- Increased risk of thrombosis with concomitant use of other JAK inhibitors
Curated Content: Needs Vetting Before Put to Clinical Use